Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT00426764Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2007
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of romidepsin in peripheral T-cell lymphoma (PTCL), sponsored by Celgene Corporation. Started Jun 2007; status: completed.
02
Drugs
romidepsin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00426764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00426764.